HNN3.0

Project cooperationUpdated on 16 January 2026

Context-specific assessment of disease model relevance for post-infection research

Founder and CEO at Intellaif AB

Stockholm, Sweden

About

Research on post-infection conditions relies on disease models in a setting characterised by heterogeneity and incomplete understanding of disease processes. Different models are often used to address different questions, yet their relevance to specific aspects of the human condition is not always systematically assessed.

We provide a context-specific, quantitative assessment of disease model relevance to human post-infection disease, examining how well individual models capture the biological aspects relevant to a given research question. By analysing models at the molecular and pathway level in relation to human disease within a structured and reproducible framework, we clarify what each model is informative for, where limitations lie, and how different models relate to each other.

This supports consortia in:

  • selecting models that are appropriate for specific scientific questions,

  • understanding why different models yield different results,

  • using complementary models where no single system is sufficient,

  • interpreting findings within the actual scope of each model, avoiding over-generalisation.

As an additional benefit, these analyses provide a transparent, evidence-based basis for justifying model selection and can highlight specific biological gaps where models could be refined or complemented to better address the research objectives.

Our contribution helps ensure that conclusions in DISEASE-03 projects are grounded in a clear and quantitative understanding of how disease models relate to the human condition they are intended to represent.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions

Organisation

Intellaif AB

Start-up

Stockholm, Sweden

Similar opportunities

  • Project cooperation

    Sex Differences in Cardiometabolism in Health and Disease

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Lukas Chmatal

    Junior Group Leader at Institute of Physiology of the Czech Academy of Sciences

    Prague, Czech Republic

  • Project cooperation

    De-risking mechanistic claims through human-relevant validation of CVD disease models

    • Partner seeks Consortium/Coordinator
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Parvin Kumar

    Founder and CEO at Intellaif AB

    Stockholm, Sweden

  • Project cooperation

    Collaboration: NAMs to advance biomedical research

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Sarka Lehtonen

    Research Director at A.I.Virtanen Institute for Molecular Sciences

    Kuopio, Finland